Lixian Wu

机构：Fujian Medical University, First People's Hospital of Foshan, Union Hospital · ORCID：0000-0001-6505-0648

发表论文 71 篇 · 总被引 1043 次 · h-index 20

代表论文

• Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial (2025 · BMJ · 被引 103)
• Ferroptosis boosted oral cancer photodynamic therapy by carrier-free Sorafenib-Ce6 self-assembly nanoparticles (2024 · Journal of Controlled Release · 被引 63)
• A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease (2024 · Hepatology International · 被引 33)
• Analysis of complete mitogenomes and phylogenetic relationships of Frontopsylla spadix and Neopsylla specialis (2023 · Frontiers in Veterinary Science · 被引 11)
• Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study (2025 · Hepatology · 被引 10)
• Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma (2024 · iScience · 被引 5)